Drew Ranieri
Stock Analyst at Morgan Stanley
(1.23)
# 3,703
Out of 5,129 analysts
170
Total ratings
44.57%
Success rate
-11.67%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $15.23 | +51.07% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $88.26 | +13.30% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $13.47 | +55.90% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $3.76 | +59.57% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $363.70 | +22.35% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $11.18 | +141.50% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $2.02 | +296.04% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $15.60 | +41.03% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $14.54 | -44.98% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $4.54 | +1,717.18% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $30.26 | +25.58% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $57.50 | +66.96% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $15.12 | +71.96% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $180.62 | +63.33% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $106.95 | +161.80% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $8.09 | -38.16% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $22.27 | +214.32% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $496.12 | -39.53% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $15.23
Upside: +51.07%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $88.26
Upside: +13.30%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $13.47
Upside: +55.90%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $3.76
Upside: +59.57%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $363.70
Upside: +22.35%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $11.18
Upside: +141.50%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $2.02
Upside: +296.04%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $15.60
Upside: +41.03%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $14.54
Upside: -44.98%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $4.54
Upside: +1,717.18%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $30.26
Upside: +25.58%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $57.50
Upside: +66.96%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $15.12
Upside: +71.96%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $180.62
Upside: +63.33%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $106.95
Upside: +161.80%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $8.09
Upside: -38.16%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $22.27
Upside: +214.32%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $496.12
Upside: -39.53%